Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Furuncular myiasis in humans is caused by two species: the Cayor worm (larvae of the African tumbu fly Cordylobia anthropophaga) and the larvae of the human botfly (Dermatobia hominis).
Biomarker and diagnostic research for furuncular myiasis has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for furuncular myiasis.
28 publications have been identified in PubMed for furuncular myiasis. Research spans Case Report / Case Series (68%), Other (11%), and Review / Meta-Analysis (7%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 19 | 68% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 2:52 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
3 |
11% |
Research summaries | 2 | 7% |
Clinical study results | 2 | 7% |
Testing and diagnosis research | 1 | 4% |
Disease patterns and progression | 1 | 4% |
D'Amico G (2026). [PMID: 42188839](https://pubmed.ncbi.nlm.nih.gov/42188839/). *Trop Med Infect Dis*. [Review / Meta-Analysis]
Lin BS (2026). [PMID: 41106760](https://pubmed.ncbi.nlm.nih.gov/41106760/). *Am J Med*. [Case Report / Case Series]
Mancinelli L (2026). [PMID: 42113858](https://pubmed.ncbi.nlm.nih.gov/42113858/). *PLoS Negl Trop Dis*. [Case Report / Case Series]
Salerni G (2026). [PMID: 41814591](https://pubmed.ncbi.nlm.nih.gov/41814591/). *Australas J Dermatol*. [Other]
Jhaveri D (2026). [PMID: 41562817](https://pubmed.ncbi.nlm.nih.gov/41562817/). *Reports (MDPI)*. [Case Report / Case Series]
Gaurav V (2025). [PMID: 39489501](https://pubmed.ncbi.nlm.nih.gov/39489501/). *Pediatr Dermatol*. [Case Report / Case Series]
Habre M (2025). [PMID: 40197533](https://pubmed.ncbi.nlm.nih.gov/40197533/). *Int J Dermatol*. [Other]
Schaffer K (2025). [PMID: 40012651](https://pubmed.ncbi.nlm.nih.gov/40012651/). *J Am Coll Emerg Physicians Open*. [Review / Meta-Analysis]
Momčilović S (2025). [PMID: 40930410](https://pubmed.ncbi.nlm.nih.gov/40930410/). *Travel Med Infect Dis*. [Case Report / Case Series]
Rench T (2025). [PMID: 40845679](https://pubmed.ncbi.nlm.nih.gov/40845679/). *J Emerg Med*. [Case Report / Case Series]
AI-curated news mentioning furuncular myiasis
Updated Aug 29, 2026
FDA has issued Emergency Use Authorizations for three animal drugs aimed at preventing and treating infestations caused by New World screwworm larvae. This decision impacts livestock including dairy cattle, horses, swine, sheep, and deer.
FDA grants Emergency Use Authorization for Bimectin (ivermectin) to prevent New World screwworm infestations in cattle. The drug is effective when administered within 24 hours of birth, during castration, or upon wound appearance.
FDA grants Emergency Use Authorization for Simparica TRIO, a chewable tablet combining sarolaner, moxidectin, and pyrantel, to treat New World screwworm infestations in dogs and puppies. This approval addresses a critical need for effective treatment against myiasis in affected animals.
FDA grants Emergency Use Authorization for CLiK Extra, a topical spray aimed at preventing New World screwworm infestations in livestock including sheep, cattle, goats, and swine. This approval addresses a critical need in veterinary medicine to combat myiasis.
A case report details advanced periorbital squamous cell carcinoma complicated by extensive facial myiasis in a homeless patient. This unique presentation highlights the intersection of severe skin cancer and parasitic infection, emphasizing the need for awareness in vulnerable populations.